A Phase 3 interventional study of Ultrasound guided Continuous Infraclavicular Brachial Plexus Block and Ultrasound guided Continuous Femoral Nerve Block in Gender Dysphoria, sponsored by Cedars-Sinai Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-17.
Sponsored by Cedars-Sinai Medical Center · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Gender Dysphoria with a site in United States — 11 open to participants now, 13 under way, 3 of them phase 3. Gender Dysphoria · United States.
Among the 31 studies in Gender Dysphoria with a site in United States, this one is the 2nd largest by planned enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2021, is one of 2 in phase 3, reaches primary completion later than 3 of the 12 other live ones, and was the 13th registered.
85 studies on the registry are indexed under Gender Dysphoria; 38 are open to participants now.
Browse Gender Dysphoria studies →11 of the 31 studies in Gender Dysphoria with a site in United States are open now. Recruiting first, the newest first:
University of Wisconsin, Madison · Sites in United States
Ages 18–45 · Healthy volunteers
University Hospitals Cleveland Medical Center · Sites in United States
Ages 19–99 · Men only
Women and Infants Hospital of Rhode Island · Sites in United States
Ages 18+ · Women only
University of Virginia · Sites in United States
Ages 18+ · Women only
Walter Reed National Military Medical Center · Sites in United States
Ages 18–65 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 31 Gender Dysphoria studies recruiting now, 15 (48%) set no upper age limit and 10 (32%) stop at 75 or younger; 7 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 1 · Phase 3 3 · Phase 4 4
First in 2017; this study’s year is marked. 3 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 640 is above the median of 55 across 31 interventional studies indexed under Gender Dysphoria.
Median enrollment 50 across the 15 interventional studies, 46 across the 16 observational. Of the 16 that completed or were terminated, 4 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 31 has an industry lead sponsor. The 10 most frequent:
Cedars-Sinai Medical Center is the lead sponsor of 457 studies on the registry; 108 are open to participants now.
Of its 65 completed or terminated interventional studies of FDA-regulated products, 49 (75%) have results posted.
Cedars-Sinai Medical Center has 1 study filed under Gender Dysphoria — fewer than ten, so there is no comparison to draw.
2 of the studies in Gender Dysphoria with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07412509University of ChicagoCan 3D Modeling Enhance Patient Understanding, Education, and Surgical Outcomes in Gender Affirming Peritoneal Vaginoplasty? | 2027-03 |
| NCT07286123University Hospitals Cleveland Medical CenterGender Affirming Vaginoplasty With Tubularized Augmented Peritoneal Cap (TAPCap) Utilizing Fish Skin Xenograft (Kerecis™) | 2027-06-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 31 studies in Gender Dysphoria with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will compare the current standard-of-care pain treatment regimen options that are available to patients who undergo gender-affirming surgery. The purpose of this research is to determine if any of these options are more (versus less) effective than the others to manage surgery related pain, after surgery.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Depending on which one of the thirteen possible gender-affirming surgeries the participant is undergoing, a combination of the following anesthetic block(s) will be used in this arm at either the pre-incision, intra-op, mid-surgery, end of surgery, or continuous time points: * Bilateral spermatic cord block (0.5% bupivacaine, 10cc per spermatic cord) * Local anesthetic (0.25% or 0.5% bupivacaine + 1:200K epinephrine) * Bilateral ultrasound guided pudendal nerve block (20-40 cc of 0.25% bupivacaine + 1:200K epinephrine) * Ultrasound guided Continuous Infraclavicular Brachial Plexus Block * Ultrasound guided Continuous Femoral Nerve Block * Pecs I \& II Block (0.25% bupivacaine: 15-30ml per side for Pecs I-III)
Other: Ultrasound guided Continuous Infraclavicular Brachial Plexus Block · Other: Ultrasound guided Continuous Femoral Nerve Block · Other: Ultrasound guided Pudendal Nerve Block · Drug: Bupivacaine · Other: Bilateral spermatic cord block · Other: Pecs I & II Block · Other: Local anesthetic
Depending on which one of the thirteen possible gender-affirming surgeries the participant is undergoing, a combination of the following anesthetic block(s) will be used in this arm at either the intra-op, post-op, or end of surgery time points: * Bilateral ultrasound-guided Transversus Abdominis Plane Block (40-60cc of 0.25% bupivacaine with 1:200K epinephrine) * Local anesthetic (0.25 or 0.5% bupivacaine + 1:200K epinephrine)
Drug: Bupivacaine · Other: Bilateral ultrasound guided Transversus Abdominis Plane Block · Other: Local anesthetic
Depending on which one of the thirteen possible gender-affirming surgeries the participant is undergoing, a combination of the following anesthetic block(s) will be used in this arm at either the mid-surgery or end of surgery time points: * Bilateral spermatic cord block (0.5% bupivacaine, 10cc per spermatic cord) * Local anesthetic (0.25 or 0.5% bupivacaine + 1:200K epinephrine)
Drug: Bupivacaine · Other: Bilateral spermatic cord block · Other: Local anesthetic
20cc of 0.25% bupivacaine + 1:200K epinephrine will be administered at start of case, 20cc of 0.25% bupivacaine + 1:200K epinephrine at end of case, and 6cc/hr of 0.25% bupivacaine at post-op \[administered by anesthesiologist\]
20cc of 0.25% bupivacaine + 1:200K epinephrine will be administered at start of case, 20cc of 0.25% bupivacaine + 1:200K epinephrine at end of case, and 6cc/hr of 0.25% bupivacaine at post-op \[administered by anesthesiologist\]
20-40cc of 0.25% bupivacaine + 1:200K epinephrine \[administered by anesthesiologist, pre-incision\]
0.25% or 0.5% with or without 1:200K epinephrine
Also known as: Marcaine
40-60cc of 0.25% bupivacaine + 1:200K epinephrine \[administered by anesthesiologist post-op or at end of surgery\]
10cc per spermatic cord of 0.5% bupivacaine \[administered by surgeon @ intraop\]
0.25% bupivacaine: 15-30mL per side for Pecs I-III
0.25% or 0.5% bupivacaine into the appropriate surgical site
Changes in peri-operative pain location and intensity over time, as measured by anatomic pain maps
Anterior and posterior illustrations of the body, with pre-defined areas involved in surgery that may be circled, will be used to define pain location. Pain scores for each circled area will be measured on a Likert-scale between 0-10, with 0 indicating no pain and 10 indicating the worst pain experienced in respondent's life.
Time frame: Any time pain is experienced, starting on the morning of post-operative Day 1 to End of Study at the final post-operative visit (average of 30 days after surgery)
Changes in opioid consumption per 24 hours, measured by total inpatient and total outpatient
Inpatient opioid consumption will be obtained from hospital records. Outpatient opioid consumption will be determined from completed medication logs. Opioid consumption will be measured per 24 hours, by hospital location (e.g., PACU versus Ward), and by post-operative day.
Time frame: Per 24 hours, starting on post-operative Day 1 to End of Study at the final post-operative visit (average of 30 days after surgery)
Change in the opioid side effect of urinary retention, as indicated by time to spontaneous voiding
Recorded time to spontaneous voiding will be collected from hospital records.
Time frame: Post-operative Day 1 to Discharge (average of 7 days after surgery)
Change in the opioid side effect of urinary retention, as measured by a Urinary Bother Symptom Score Questionnaire
A Urinary Bother Symptom Score Questionnaire, obtained from the American Urological Association, will assess the frequency of different urinary problems, such as incomplete emptying, intermittency, and urgency. Each urinary problem will be measured on a scale from 0 to 5, with 0 indicating "none/not at all" and 5 indicating "almost always."
Time frame: Pre-operative visit, Discharge (average of 7 days after surgery), and End of Study/final post-operative visit (average of 30 days after surgery)
Change in the opioid side effect of decreased GI motility and ileus, as indicated by number of post-operative days until commencement of regular passage of flatus
Recorded number of post-operative days until commencement of regular passage of flatus will be obtained from hospital records.
Time frame: Post-operative Day 1 to Discharge (average of 7 days after surgery)
Change in the opioid side effect of nausea, as indicated by number of post-operative days to toleration of liquid diet and regular diet, as well as reported experience of nausea
Recorded number of post-operative days and experience of nausea will be obtained from hospital records.
Time frame: Post-operative Day 1 to Discharge (average of 7 days after surgery)
Post-operative length of inpatient stay
Length of inpatient stay will be obtained from hospital records as the recorded number of days spent inpatient after surgery
Time frame: Post-operative Day 1 to Discharge (average of 7 days after surgery)
Global satisfaction with respect to pain and physical comfort, as measured by a Quality of Recovery 15-Item Inventory
Questions 1-10 will assess global well-being and physical comfort, such as ability to return to work or usual home activities, feeling rested, ability to enjoy food, and general feelings of well-being. These questions will be rated on a scale of 0 to 10, with 0 indicating none of the time (poor) and 10 indicating all of the time (excellent). Questions 11-15 will assess pain and physical comfort, such as presence of moderate/severe pain, nausea or vomiting, worried or anxious feelings, and sad or depressed feelings. These questions will be rated on a scale of 0 to 10, with 0 indicating all of the time (poor) and 10 indicating none of the time (excellent).
Time frame: Daily, starting on the morning of post-operative Day 1 to End of Study at the final post-operative visit (average of 30 days after surgery)
Frequency of treatment complications
Treatment complications, such as hematoma, infection, etc., will only include those that are determined to be related to the study treatment.
Time frame: End of study (average of 30 days after surgery)
Time to mobilization
The recorded number of days to mobilization will be obtained from hospital records.
Time frame: Post-operative Day 1 to Discharge (average of 7 days after surgery)
Time to first day of bowel movement
The recorded number of days to first bowel movement will be obtained from hospital records.
Time frame: Post-operative Day 1 to Discharge (average of 7 days after surgery)
Number of participants with any hospital readmission within 30 days of discharge
Time frame: 30 days after Day of Discharge (average of 7 days after surgery)
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2021 (actual). Primary completion is estimated for Sep 2026, 58 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.